A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
Brief description of study
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug CYT-0851 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-00047
ClinicalTrials.gov Identifier: NCT03997968
Principal Investigator:
Nina Beri.
Other Investigators:
Scot Niglio,
Jonathan B Kahn,
Carol M Lee,
Vamsidhar Velcheti,
Zujun Li,
Jessica Wang,
Ann M Riccobene,
Maya Dimitrova,
Joshua K Sabari,
Nila Theresa De La Rosa,
Sally Lau,
Cosmin Adrian Tegla,
Christy Lynn Spalink,
Kristen Spencer,
Elaine Shum,
Janice Mehnert,
Douglas K Marks,
Nora Russo,
Salman Rafi Punekar,
Avital Benson,
Keriann M Scavone,
Bhavana Pothuri,
Elise M Zahriah,
Kathleen M Madden,
Christina Grace Wilson,
Maryann J Kwa,
Kathleen M Lutz.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
